Literature DB >> 880972

Distribution and elimination of digoxin in infants.

G Wettrell.   

Abstract

The distribution and elimination of intravenous digoxin were investigated in seven neonates and infants with heart failure. Serum digoxin concentrations during a 24 h period were determined by radioimmunoassay, using 125I as tracer. The serum values declined biexponentially after the injection and could be fitted to a two-compartment open model by non-linear least-squares regression. The calculated mean half-lives of the distribution (alpha) phase in neonates and infants were 37 and 28 min, respectively. The mean half-life of the elimination (beta) phase in neonates was 44 h, as compared to 19 h in infants. The mean volume of the central compartment and the mean volume of distribution at steady-state were calculated to be 1.3 and 9.91/kg, respectively; no significant differences between neonates and infants were found. The relation between these volumes indicates that digoxin is extensively distributed in tissues. The steady-state distribution volumes of digoxin in neonates and infants exceed those reported in adults. The larger volume of distribution might explain in part why infants with cardiac insufficiency require larger doses of digoxin than adults (on a mg/kg body weight basis) to obtain the same serum concentrations. Elimination of digoxin from the body was slower in neonates than in infants.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 880972     DOI: 10.1007/bf00566529

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  18 in total

1.  Pharmacokinetics of digoxin in normal subjects after intravenous bolus and infusion doses.

Authors:  J R Koup; D J Greenblatt; W J Jusko; T W Smith; J Koch-Weser
Journal:  J Pharmacokinet Biopharm       Date:  1975-06

2.  Post-mortem distribution and tissue concentrations of digoxin in infants and adults.

Authors:  K E Andersson; A Bertler; G Wettrell
Journal:  Acta Paediatr Scand       Date:  1975-05

3.  Simplification of drug dosage calculation by application of the surface area principle.

Authors:  J D CRAWFORD; M E TERRY; G M ROURKE
Journal:  Pediatrics       Date:  1950-05       Impact factor: 7.124

4.  Serum protein binding of digoxin in newborn infants.

Authors:  R Gorodischer; J Krasner; S J Yaffe
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1974-10

5.  Shortcomings in pharmacokinetic analysis by conceiving the body to exhibit properties of a single compartment.

Authors:  S Riegelman; J C Loo; M Rowland
Journal:  J Pharm Sci       Date:  1968-01       Impact factor: 3.534

6.  An improved method of estimating digoxin in human plasma.

Authors:  A Bertler; A Redfors
Journal:  Clin Pharmacol Ther       Date:  1970 Sep-Oct       Impact factor: 6.875

7.  Blood levels of drug at the equilibrium state after multiple dosing.

Authors:  J G Wagner; J I Northam; C D Alway; O S Carpenter
Journal:  Nature       Date:  1965-09-18       Impact factor: 49.962

8.  Concentrations of digoxin in plasma and urine in neonates, infants, and children with heart disease.

Authors:  G Wettrell; K E Andersson; A Bertler; N R Lundström
Journal:  Acta Paediatr Scand       Date:  1974-09

9.  Binding of digitoxin and some related cardenolides to human plasma proteins.

Authors:  D S Lukas; A G De Martino
Journal:  J Clin Invest       Date:  1969-06       Impact factor: 14.808

10.  Tritiated digoxin. 18. Studies in infants and children.

Authors:  W T Dungan; J E Doherty; C Harvey; F Char; G V Dalrymple
Journal:  Circulation       Date:  1972-11       Impact factor: 29.690

View more
  14 in total

Review 1.  Some comments and suggestions concerning population pharmacokinetic modeling, especially of digoxin, and its relation to clinical therapy.

Authors:  Roger W Jelliffe
Journal:  Ther Drug Monit       Date:  2012-08       Impact factor: 3.681

Review 2.  Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part II).

Authors:  J B Besunder; M D Reed; J L Blumer
Journal:  Clin Pharmacokinet       Date:  1988-05       Impact factor: 6.447

3.  Drug interactions--their mechanism and implications.

Authors:  H M Lal
Journal:  Indian J Pediatr       Date:  1987 Jan-Feb       Impact factor: 1.967

4.  Maturation of caffeine elimination in infancy.

Authors:  J V Aranda; J M Collinge; R Zinman; G Watters
Journal:  Arch Dis Child       Date:  1979-12       Impact factor: 3.791

5.  Digoxin dosage schedules for neonates and infants based on pharmacokinetic considerations.

Authors:  L Nyberg; G Wettrell
Journal:  Clin Pharmacokinet       Date:  1978 Nov-Dec       Impact factor: 6.447

6.  A standard approach to compiling clinical pharmacokinetic data.

Authors:  L B Sheiner; L Z Benet; L A Pagliaro
Journal:  J Pharmacokinet Biopharm       Date:  1981-02

7.  Pharmacokinetics and dosagae of digoxin in neonates and infants.

Authors:  L Nyberg; G Wettrell
Journal:  Eur J Clin Pharmacol       Date:  1980-07       Impact factor: 2.953

8.  Single daily dose of digoxin for maintenance therapy of infants and children with cardiac disease: is it reliable?

Authors:  M Bakir; A Bilgiç
Journal:  Pediatr Cardiol       Date:  1994 Sep-Oct       Impact factor: 1.655

Review 9.  Pharmacokinetics of cardiovascular drugs in children. Inotropes and vasopressors.

Authors:  C Steinberg; D A Notterman
Journal:  Clin Pharmacokinet       Date:  1994-11       Impact factor: 6.447

10.  Pharmacokinetics of digoxin in the turkey and comparison with other species.

Authors:  E Park; S Einzig; N A Staley; G R Noren
Journal:  J Pharmacokinet Biopharm       Date:  1981-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.